JD Supra9h
Teva v. Amneal Oral Arguments and Claim Construction Order: Recent Developments in the Ongoing Debate Over the Orange Book Listing of Device Patents
As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange ...
Medpage Today on MSN2d
Will Trump Adopt the Current FTC's Antitrust Posture?
The Federal Trade Commission (FTC) under Chair Lina Khan took an aggressive approach to tackling anticompetitive behavior in ...
JD Supra26d
Teva Ordered to Delist Inhaler Patents From FDA Orange Book
The court held that those patents did not satisfy the requirements for listing in the Orange Book, finding that the patents did not claim the drug or drug product for which the associated New Drug ...
Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval
Iterum Therapeutics ( (ITRM) ) has released its Q3 earnings. Here is a breakdown of the information Iterum Therapeutics presented to its ...
BioWorld14d
Change is the constant in wake of US elections
The drug and device industries have a lot hinging on the results of the Nov. 5 U.S. presidential and congressional elections.
GlobalData on MSN9d
Trump triumphs but impact on healthcare industry remains unclear
Trump has not been vocal about healthcare policies but indicated that RFK Jr will have a big influence on the sector.
TMCnet1d
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
The Company currently has 12 listed patents for IGALMI in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) with expiration dates between 2037 and 2043. Recently ...